Meta-analysis of 35 studies (664 patients) of JAK inhibitors in acute severe ulcerative colitis: short-term pooled clinical response was 77.9% with tofacitinib and 86.5% with upadacitinib, with colectomy rates of 11.5% and 11.2%.
Meta-analysisn = 664 patients
Jena et al. Effectiveness and Safety of Janus Kinase Inhibitors in Acute Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis